The FDA has approved Trelstar 22.5mg (triptorelin pamoate for injectable suspension, from Watson) for the palliative treatment of advanced prostate cancer.

The FDA has approved a generic version of Flomax (tamsulosin HCl capsules, from Boehringer Ingelheim) for the treatment of benign prostatic hyperplasia (BPH).

Antares Pharma announced that it has completed enrollment in the double-blind portion of their Phase 3 trial of Anturol (transdermal oxybutynin ATD gel) for the treatment of overactive bladder (OAB).

Treatment outcomes are similar to those of laparoscopic procedures, but operating times are shorter and surgeons operate with ergonomic comfort.

Although the American Urological Association (AUA) "applauds" the new guidance statement on prostate-cancer detection issued by the American Cancer Society (ACS), the two organizations have divergent opinions regarding when baseline screening should begin.

Study reveals survival benefit after curative treatment.